May 13, 2025
DURECT Corporation Reports First Quarter 2025 Financial Results and Provides Business Update
Mar 26, 2025
DURECT Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Mar 19, 2025
DURECT Corporation to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide a Business Update
Jan 28, 2025
DURECT Corporation Announces Publication of Larsucosterol Phase 2b Results in NEJM Evidence
Nov 13, 2024
DURECT Corporation Reports Third Quarter 2024 Financial Results and Provides Business Update
Sep 25, 2024
DURECT Corporation Announces Phase 3 Registrational Trial Design for Larsucosterol in Alcohol-associated Hepatitis
Sep 04, 2024
DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference
Aug 07, 2024
DURECT Corporation to Announce Second Quarter 2024 Financial Results and Provide a Business Update
May 21, 2024
DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis
Apr 30, 2024
DURECT Corporation Announces Late-Breaking Oral Presentation at the EASL Congress 2024 to Discuss AHFIRM Phase 2b Data in Alcohol-Associated Hepatitis
Mar 20, 2024
DURECT Corporation to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update
Feb 04, 2021
DURECT Corporation Announces Pricing of $42.5 Million Public Offering of Common Stock
Jan 25, 2021
DURECT Corporation Announces First Patient Dosed in Phase 2b AHFIRM Study of DUR-928 in Severe Alcohol-Associated Hepatitis
Dec 16, 2020
DURECT Corporation Announces DUR-928 Granted FDA Fast Track Designation for Treatment of Alcoholic Hepatitis
Dec 07, 2020
DURECT Corporation to Sell its LACTEL® Absorbable Polymer Product Line to Evonik for $15 Million
Nov 13, 2020
DURECT Corporation Announces Additional Safety Data and Efficacy Signals from Phase 1b Clinical Trial of DUR-928 in NASH Patients at The Liver Meeting Digital Experience(TM) 2020
Nov 10, 2020
DURECT Corporation to Host Webinar on the Treatment of Alcoholic Hepatitis Featuring Chief Medical Officer Dr. Norman Sussman
Nov 02, 2020
DURECT Corporation Announces Third Quarter 2020 Financial Results and Update of Programs
Nov 02, 2020
DURECT Corporation Appoints Dr. Norman Sussman as Chief Medical Officer
Oct 05, 2020
DURECT Corporation to Present Additional Safety and Efficacy Signals from Phase 1b Clinical Trial of DUR-928 in NASH Patients at The Liver Meeting Digital Experience(TM) 2020